Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICH Guide Aims To Facilitate Pediatric Trials And Reduce Animal Testing

Offers Harmonized Approach On Juvenile Animal Studies

Executive Summary

A new international guideline on non-clinical safety testing in support of pediatric drug development aims to cut unnecessary use of animals.

You may also be interested in...



EFPIA Laments 'Unfortunate' Exclusions From ICH Guide On Nonclinical Pediatric Safety

Europe’s research-based pharmaceutical industry has suggested changes to the draft ICH S11 guideline on nonclinical safety studies for supporting pediatric development programs.

New ICH Guide To Eliminate ‘Discordant Advice’ On Juvenile Animal Studies

Experts at the International Council for Harmonisation have nearly completed the first draft of a guideline that explains in which situations nonclinical juvenile animal testing is considered informative and necessary to support pediatric drug development. The guideline is expected to address the "discordant advice" that different regulatory agencies currently offer companies in relation to such studies.

COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data

The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel